Valuation ORIC Pharmaceuticals, Inc. Börse Stuttgart
Stocks
4TZ
US68622P1093
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.442 EUR | -0.99% |
|
-5.67% | +36.84% |
Company Valuation: ORIC Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 578.9 | 264.8 | 501.9 | 569.5 | 796.6 | 1,123 | - | - |
| Change | - | -54.26% | 89.55% | 13.47% | 39.89% | 40.99% | - | - |
| Enterprise Value (EV) 1 | 578.9 | 264.8 | 266.8 | 569.5 | 751 | 1,014 | 891.8 | 895.1 |
| Change | - | -54.26% | 0.78% | 113.42% | 31.87% | 35% | -12.03% | 0.36% |
| P/E | -7.1x | -2.62x | -4.69x | -4.41x | -5.56x | -7.44x | -6.74x | -5.99x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | 0.4x | 0.66x | 0.3x | 8.79x | -0.6x | -0.5x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 156x |
| EV / Revenue | - | - | - | - | - | - | - | 124x |
| EV / EBITDA | -7.42x | -2.92x | -2.43x | -4.02x | -5.3x | -6.15x | -4.79x | -4.97x |
| EV / EBIT | -7.34x | -2.89x | -2.41x | -3.99x | -5.25x | -6x | -4.56x | -3.82x |
| EV / FCF | -9.57x | -3.43x | -3.08x | -5x | -6.72x | -9.48x | -6.86x | - |
| FCF Yield | -10.4% | -29.2% | -32.4% | -20% | -14.9% | -10.6% | -14.6% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | -1.458 | -1.609 | -1.811 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 7.222 |
| EBITDA 1 | -77.97 | -90.8 | -109.7 | -141.8 | -141.8 | -164.8 | -186.1 | -180 |
| EBIT 1 | -78.87 | -91.77 | -110.8 | -142.9 | -143 | -169 | -195.7 | -234.1 |
| Net income 1 | -78.72 | -89.12 | -100.7 | -127.8 | -129.5 | -156.3 | -189.6 | -241.8 |
| Net Debt 1 | - | - | -235 | - | -45.67 | -109.3 | -231.3 | -228.1 |
| Reference price 2 | 14.70 | 5.89 | 9.20 | 8.07 | 8.18 | 10.85 | 10.85 | 10.85 |
| Nbr of stocks (in thousands) | 39,382 | 44,953 | 54,552 | 70,567 | 97,389 | 103,518 | - | - |
| Announcement Date | 3/21/22 | 3/16/23 | 3/11/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.57x | 6.33x | 13.8x | 1.56% | 54.88B | |
| 32.72x | 8.29x | 25.68x | 0.06% | 54.63B | |
| -44.31x | 14.51x | -42.32x | -.--% | 25.06B | |
| -18.2x | 4.33x | -7.58x | -.--% | 23.14B | |
| 25x | 4.9x | 12.9x | -.--% | 19.87B | |
| 24.48x | 4.79x | 15.58x | -.--% | 17.55B | |
| 49.34x | 20.07x | 51.69x | 0.07% | 16.5B | |
| -539.24x | 37.99x | -4235.53x | -.--% | 15.75B | |
| 17.75x | 5.16x | 12.01x | -.--% | 14.2B | |
| Average | -47.99x | 11.82x | -461.53x | 0.19% | 26.84B | |
| Weighted average by Cap. | -21.17x | 10.13x | -265.84x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORIC Stock
- 4TZ Stock
- Valuation ORIC Pharmaceuticals, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
